1.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

2.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

3.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

4.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

5.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

6.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

7.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

8.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

9.

Clinical characteristics and humoral immune response in healthcare workers with COVID-19 in a teaching hospital in Belgium.

1.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

2.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

3.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

4.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

5.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

6.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

7.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

8.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

9.

Development of a flowchart reflecting the current attitude and approach towards idiopathic overactive bladder treatment in Belgium: A Delphi study.

1.

Improved survival in patients with head and neck cancer treated in higher volume centres: A population-based study in Belgium.

2.

Improved survival in patients with head and neck cancer treated in higher volume centres: A population-based study in Belgium.

3.

Improved survival in patients with head and neck cancer treated in higher volume centres: A population-based study in Belgium.

1.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

2.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

3.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

4.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

5.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

6.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

7.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

8.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

9.

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

1.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

2.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

3.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

4.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

5.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

6.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

7.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

8.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

9.

Novel vancomycin resistance gene cluster in ST1486, Belgium, June 2021.

1.

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.

2.

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.

3.

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.

4.

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.

5.

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.

6.

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.

7.

Monoclonal Antibody Therapy for SARS-CoV-2 Infection in Kidney Transplant Recipients: A Case Series From Belgium.

1.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

2.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

3.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

4.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

5.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

6.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

7.

Rapid Decline in Vaccine-induced Anti-SARS-CoV-2 Antibody Titers 3 Months After Kidney Transplantation: A Case Series From Belgium.

1.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

2.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

3.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

4.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

5.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

6.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

7.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

8.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

9.

Spotlight influenza: Extending influenza surveillance to detect non-influenza respiratory viruses of public health relevance: analysis of surveillance data, Belgium, 2015 to 2019.

1.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

2.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

3.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

4.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

5.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

6.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

7.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

8.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

9.

ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in...

1.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

2.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

3.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

4.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

5.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

6.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

7.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

8.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.

9.

Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update.